Targeting NER pathways can enhance the effectiveness of existing cancer treatments. Inhibitors of key NER proteins are being explored to sensitize cancer cells to DNA-damaging agents. For example, inhibiting XPF-ERCC1 could potentiate the effects of platinum-based therapies.